Eluvia demonstrated a statistically significant difference in primary patency and half the TLR rate vs. Zilver PTX at 12 months

 

12-month results from IMPERIAL, the world's first head-to-head DES SFA Trial1
Presented at LINC 2020

Kaplan-Meier Primary Patency Rate: 12-Month Results chart

CLINICAL-DRIVEN TLR RATE

  • In IMPERIAL RCT and as reported in The Lancet, 1-year ITT, CEC adjudicated mortality rates were 2.1% (6/292) for Eluvia and 4.0% (6/150) for Zilver PTX (p=0.23).
  • *Kaplan Meier Estimate; Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.
  • ** Gray, WA TCT 2018.
  • † Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.
  • 1. IMPERIAL Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against Cook Medical’s Zilver™ PTX™ Stent, single-blind, non-inferiority design; independent core lab adjudication. Superiority determined in a post hoc analysis that was specified prior to unblinding. 12-Month Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value = 0.0144).

 

12-Month Remarkable and Consistent Results in Complex Lesions

12-moth Remarkable and Consistent Results in Complex Lesions
*Kaplan Meier Estimate; Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.
** Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.
1. Intention to treat. Müller-Hülsbeck S, LINC 2019.
2. In IMPERIAL RCT, Eluvia K-M Primary Patency was 92.1% vs. 81.8% for Zilver PTX at 12 months.
3. Golzar, J. et al, Journal of Endovascular Therapy, Jan 2020. https://doi.org/10.1177/1526602820901723
4. In IMPERIAL Diabetic Subgroup, Eluvia K-M Primary Patency was 95.2% vs. 81.5% for Zilver PTX at 12 months. Diabetes = medically-treated diabetic patients.
5. PSVR < 2.0.
6. Moderate and severely calcified.

 

Better patient outcomes with Eluvia at a lower cost
based on comparison with Zilver PTX treatment

improve financial health.
  • Boston Scientific’s ELUVIA Drug-Eluting Stent and Coronary Paclitaxel-Eluting Stent Clinical Experience.
    Available at: https://www.fda.gov/media/128145/download [Accessed July 4 2019]Kbr/> Gray WA et al. Lancet. 2018 Oct 27;392(10157):1541-1551
    2-Year Results from IMPERIAL Trail; Presented at LINC 2020
 
Increase Operational Efficiencies
  • Boston Scientific’s ELUVIA Drug-Eluting Stent and Coronary Paclitaxel-Eluting Stent Clinical Experience.
    Available at: https://www.fda.gov/media/128145/download [Accessed July 4 2019]Kbr/> Gray WA et al. Lancet. 2018 Oct 27;392(10157):1541-1551
    2-Year Results from IMPERIAL Trail; Presented at LINC 2020

IMPERIAL Trial Overview

Objective

Evaluate the safety and effectiveness of the Boston Scientific Corporation ELUVIA™ Drug-Eluting Vascular Stent System for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length.

IMPERIAL Trial Design

Global multi-center, 2:1 randomization against Cook Medical’s Zilver™ PTX™ Stent, controlled, single-blind, non-inferiority trial; core lab adjudicated
  • 465 (RCT) patients across 64 sites
  • 5-year follow-up
  • Degree of stenosis ≥ 70% (visual angiographic assessment)
  • Vessel diameter ≥ 4 mm and ≤ 6 mm
  • Total lesion length ≥ 30 mm and ≤ 140 mm

Baseline Characteristics

Baseline Characteristics
Baseline Characteristics
Sign Up Today

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore Resources

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

 

 

Top